ArticleScientific reports2025
Emergency response for recently isolated Foot and Mouth Disease virus type A Africa in Egypt 2022.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Foot-and-mouth disease virus-like particle mRNA vaccine induces strong humoral and cellular immunity.Applied microbiology and biotechnology · 2026Article
- Optimization of untranslated regions enhances antigen expression and immunogenicity of FMDV P12A3C mRNA vaccine.Virology journal · 2026Article
- Article
- Article
- Molecular characterisation of foot-and-mouth disease viruses collected from Bangladesh during 2021-23: evidence for trans-pool spread of exotic viral lineages.Veterinary research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot and mouth disease (FMD) is a highly contagious viral infection affecting cloven-hoofed ruminants, leading to significant economic losses. In 2022, Egypt faced a severe outbreak of Foot and Mouth Disease (FMD) caused by the A/Africa/G-IV variant. This study assessed the efficacy of local and imported FMDV vaccines (A Iran-05 lineage) against this new variant using in vitro and in vivo methods. Sera from vaccinated calves showed inadequate cross-protection, with mean r1-values of 0.235 and 0.243 for local and imported vaccines, respectively. Challenge tests indicated low protection levels (20% and 40%) against A/Africa/G-IV compared with A/Iran/05. Current vaccines were deemed ineffective, prompting a formulation update incorporating the variant. The modified vaccine is now deployed in proactive vaccination efforts to address the evolving FMD outbreak.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.